Loading clinical trials...
Loading clinical trials...
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors.
This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors. CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM. Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Klinik für Radioonkologie und Strahlentherapie
Berlin, Germany
Start Date
February 17, 2021
Primary Completion Date
February 1, 2022
Completion Date
May 1, 2022
Last Updated
May 14, 2021
120
ESTIMATED participants
CTC isolation by HSP70
DIAGNOSTIC_TEST
Lead Sponsor
Charite University, Berlin, Germany
Collaborators
NCT04704661
NCT06066138
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions